{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T10:54:26Z","timestamp":1794567266724,"version":"4.9.1"},"publisher-location":"New York, NY","reference-count":66,"publisher":"Springer New York","isbn-type":[{"value":"9781493978243","type":"print"},{"value":"9781493978250","type":"electronic"}],"license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018]]},"DOI":"10.1007\/978-1-4939-7825-0_25","type":"book-chapter","created":{"date-parts":[[2018,5,31]],"date-time":"2018-05-31T08:44:16Z","timestamp":1527756256000},"page":"549-571","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Methods to Quantify Cell Signaling and GPCR Receptor Ligand Bias: Characterization of Drugs that Target the Endocannabinoid Receptors in Huntington\u2019s Disease"],"prefix":"10.1007","author":[{"given":"Amina M.","family":"Bagher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert B.","family":"Laprairie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie E. M.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen M.","family":"Denovan-Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,1]]},"reference":[{"key":"25_CR1","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.tibs.2013.05.003","volume":"38","author":"J Labbadia","year":"2013","unstructured":"Labbadia J, Morimoto RI (2013) Huntington\u2019s disease: underlying molecular mechanisms and emerging concepts. Trends Biochem Sci 38:378\u2013385","journal-title":"Trends Biochem Sci"},{"key":"25_CR2","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/nrneurol.2014.24","volume":"10","author":"CA Ross","year":"2014","unstructured":"Ross CA, Aylward EH, Wild EJ et al (2014) Huntington disease: natural history, biomarkers and prospects for therapeutics. Nat Rev Neurol 10:204\u2013216","journal-title":"Nat Rev Neurol"},{"key":"25_CR3","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1089\/10430340050111377","volume":"11","author":"AC Bachoud-Levi","year":"2000","unstructured":"Bachoud-Levi AC, Deglon N, Nguyen JP et al (2000) Neuroprotective gene therapy for Huntington\u2019s disease using a polymer encapsulated BHK cell line engineered to secrete human CNTF. Hum Gene Ther 11:1723\u20131729","journal-title":"Hum Gene Ther"},{"key":"25_CR4","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1089\/hum.2004.15.968","volume":"15","author":"J Bloch","year":"2004","unstructured":"Bloch J, Bachoud-Levi AC, Deglon N et al (2004) Neuroprotective gene therapy for Huntington\u2019s disease, using polymer-encapsulated cells engineered to secrete human ciliary neurotrophic factor: results of a phase I study. Hum Gene Ther 15:968\u2013975","journal-title":"Hum Gene Ther"},{"key":"25_CR5","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.nbd.2011.12.030","volume":"48","author":"S Ramaswamy","year":"2012","unstructured":"Ramaswamy S, Kordower JH (2012) Gene therapy for Huntington\u2019s disease. Neurobiol Dis 48:243\u2013254","journal-title":"Neurobiol Dis"},{"key":"25_CR6","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.nbd.2016.03.027","volume":"97","author":"RT Bartus","year":"2016","unstructured":"Bartus RT, Johnson EM (2016) Clinical tests of neurotrophic factors for human neurodegenerative diseases: Part 1. Where have we been and what have we learned? Neurobiol Dis 97:156\u2013168","journal-title":"Neurobiol Dis"},{"key":"25_CR7","first-page":"9","volume":"28","author":"W Yang","year":"2016","unstructured":"Yang W, Tu Z, Sun Q, Li XJ (2016) CRISPR\/Cas9: implications for modeling and therapy of neurodegenerative diseases. Front Mol Neurosci 28:9\u201330","journal-title":"Front Mol Neurosci"},{"key":"25_CR8","first-page":"81","volume":"51","author":"OR Adam","year":"2008","unstructured":"Adam OR, Jankovic J (2008) Symptomatic treatment of Huntington disease. Neurotherapeutics 51:81\u201397","journal-title":"Neurotherapeutics"},{"key":"25_CR9","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s13311-013-0244-z","volume":"11","author":"F Frankc","year":"2014","unstructured":"Frankc F (2014) Treatment of Huntington\u2019s disease. Neurotherapeutics 11:153\u2013160","journal-title":"Neurotherapeutics"},{"key":"25_CR10","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1517\/14656566.2016.1109630","volume":"17","author":"SL Mason","year":"2016","unstructured":"Mason SL, Barker RA (2016) Advancing pharmacotherapy for treating Huntington\u2019s disease: a review of the existing literature. Expert Opin Pharmacol 17:41\u201352","journal-title":"Expert Opin Pharmacol"},{"key":"25_CR11","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/nrd2518","volume":"7","author":"MC Lagerstr\u00f6m","year":"2008","unstructured":"Lagerstr\u00f6m MC, Schi\u00f6th HB (2008) Structural diversity of G protein-coupled receptors and significance for drug discovery. Nat Rev Drug Discov 7:339\u2013357","journal-title":"Nat Rev Drug Discov"},{"key":"25_CR12","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/nrm2299","volume":"9","author":"WM Oldham","year":"2008","unstructured":"Oldham WM, Hamm HE (2008) Heterotrimeric G protein activation by protein-coupled receptors. Nat Rev Mol Cell Biol 9:60\u201371","journal-title":"Nat Rev Mol Cell Biol"},{"key":"25_CR13","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/nature08144","volume":"459","author":"DM Rosenbaum","year":"2009","unstructured":"Rosenbaum DM, Rasmussen SG, Kobilka BK (2009) The structure and function of G-protein-coupled receptors. Nature 459:356\u2013363","journal-title":"Nature"},{"key":"25_CR14","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1210\/me.2009-0473","volume":"24","author":"RP Millar","year":"2010","unstructured":"Millar RP, Newton CL (2010) The year in G protein-coupled receptor research. Mol Endocrinol 24:261\u2013274","journal-title":"Mol Endocrinol"},{"key":"25_CR15","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1021\/cn200111m","volume":"3","author":"T Kenakin","year":"2012","unstructured":"Kenakin T, Watson C, Muniz-Medina V et al (2012) A simple method for quantifying functional selectivity and agonist bias. ACS Chem Neurosci 3:193\u2013203","journal-title":"ACS Chem Neurosci"},{"key":"25_CR16","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/j.1369-1600.2008.00108.x","volume":"13","author":"RG Pertwee","year":"2008","unstructured":"Pertwee RG (2008) Ligands that target cannabinoid receptors in the brain: from THC to anandamide and beyond. Addict Biol 13:147\u2013159","journal-title":"Addict Biol"},{"key":"25_CR17","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/346561a0","volume":"346","author":"LA Matsuda","year":"1990","unstructured":"Matsuda LA, Lolait SJ, Brownstein MJ et al (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346:561\u2013564","journal-title":"Nature"},{"key":"25_CR18","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.bbrc.2008.05.077","volume":"372","author":"WG Tharp","year":"2008","unstructured":"Tharp WG, Lee YH, Maple RL, Pratley RE (2008) The cannabinoid CB1 receptor is expressed in pancreatic delta-cells. Biochem Biophys Res Commun 372:595\u2013600","journal-title":"Biochem Biophys Res Commun"},{"key":"25_CR19","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1002\/dmrr.764","volume":"23","author":"D Cota","year":"2007","unstructured":"Cota D (2007) CB1 receptors: emerging evidence for central and peripheral mechanisms that regulate energy balance, metabolism, and cardiovascular health. Diabetes Metab Res Rev 23:507\u2013517","journal-title":"Diabetes Metab Res Rev"},{"key":"25_CR20","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/365061a0","volume":"365","author":"S Munro","year":"1993","unstructured":"Munro S, Thomas KL, Abu-Shaar M (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature 365:61\u201365","journal-title":"Nature"},{"key":"25_CR21","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/syn.20050","volume":"53","author":"E N\u00fa\u00f1ez","year":"2004","unstructured":"N\u00fa\u00f1ez E, Benito C, Pazos MR et al (2004) Cannabinoid CB2 receptors are expressed by perivascular microglia cells in the human brain: an immunohistochemical study. Synapse 53:208\u2013213","journal-title":"Synapse"},{"key":"25_CR22","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.tips.2006.11.001","volume":"28","author":"J Fern\u00e1ndez-Ruiz","year":"2006","unstructured":"Fern\u00e1ndez-Ruiz J, Romero J, Velasco G et al (2006) Cannabinoid CB2 receptor: a new target for controlling neural cell survival. Trends Pharmacol Sci 28:39\u201345","journal-title":"Trends Pharmacol Sci"},{"key":"25_CR23","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/alcalc\/agh110","volume":"40","author":"F Rodriguez de Fonseca","year":"2005","unstructured":"Rodriguez de Fonseca F, Del Arco I, Bermudez-Silva FJ et al (2005) The endocannabinoid system: physiology and pharmacology. Alcohol 40:2\u201314","journal-title":"Alcohol"},{"key":"25_CR24","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1038\/372686a0","volume":"372","author":"V Marzo Di","year":"1994","unstructured":"Di Marzo V, Fontana A, Cadas H et al (1994) Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 372:686\u2013691","journal-title":"Nature"},{"key":"25_CR25","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S0014-2999(01)01182-7","volume":"425","author":"N Stella","year":"2001","unstructured":"Stella N, Piomelli D (2001) Receptor-dependent formation of endogenous cannabinoids in cortical neurons. Eur J Pharmacol 425:189\u2013196","journal-title":"Eur J Pharmacol"},{"key":"25_CR26","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1126\/science.1470919","volume":"258","author":"WA Devane","year":"1992","unstructured":"Devane WA, Hanus L, Breuer A et al (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258:1946\u20131949","journal-title":"Science"},{"key":"25_CR27","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/0006-2952(95)00109-D","volume":"50","author":"R Mechoulam","year":"1995","unstructured":"Mechoulam R, Ben-Shabat S, Hanus L et al (1995) Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50:83\u201390","journal-title":"Biochem Pharmacol"},{"key":"25_CR28","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/3-540-26573-2_2","volume":"168","author":"AC Howlett","year":"2005","unstructured":"Howlett AC (2005) Cannabinoid receptor signaling. Handb Exp Pharmacol 168:53\u201379","journal-title":"Handb Exp Pharmacol"},{"key":"25_CR29","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1677\/JME-08-0190","volume":"44","author":"G Turu","year":"2010","unstructured":"Turu G, Hunyady L (2010) Signal transduction of the CB1 cannabinoid receptor. J Mol Endocrinol 44:75\u201385","journal-title":"J Mol Endocrinol"},{"key":"25_CR30","doi-asserted-by":"publisher","first-page":"90","DOI":"10.2174\/1574889810999160719105433","volume":"10","author":"R Ranieri","year":"2016","unstructured":"Ranieri R, Laezza C, Bifulco M et al (2016) Endocannabinoid system in neurological disorders. Recent Pat CNS Drug Discov 10:90\u2013112","journal-title":"Recent Pat CNS Drug Discov"},{"key":"25_CR31","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/S0306-4522(00)00157-3","volume":"98","author":"EM Denovan-Wright","year":"2000","unstructured":"Denovan-Wright EM, Robertson HA (2000) Cannabinoid receptor messenger RNA levels decrease in a subset of neurons of the lateral striatum, cortex and hippocampus of transgenic Huntington\u2019s disease mice. Neuroscience 98:705\u2013713","journal-title":"Neuroscience"},{"key":"25_CR32","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0306-4522(00)00008-7","volume":"97","author":"M Glass","year":"2000","unstructured":"Glass M, Dragunow M, Faull RL (2000) The pattern of neurodegeneration in Huntington\u2019s disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington\u2019s disease. Neuroscience 97:505\u2013519","journal-title":"Neuroscience"},{"key":"25_CR33","doi-asserted-by":"publisher","first-page":"41","DOI":"10.2174\/157488912798842278","volume":"7","author":"O Sagredo","year":"2012","unstructured":"Sagredo O, Pazos MR, Valdeolivas S, Fernandez-Ruiz J (2012) Cannabinoids: novel medicines for the treatment of Huntington\u2019s disease. Recent Pat CNS Drug Discov 7:41\u201348","journal-title":"Recent Pat CNS Drug Discov"},{"key":"25_CR34","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.nbd.2014.08.009","volume":"71","author":"AV Naydenov","year":"2014","unstructured":"Naydenov AV, Sepers MD, Swinney K et al (2014a) Genetic rescue of CB1 receptors on medium spiny neurons prevents loss of excitatory striatal synapses but not motor impairment in HD mice. Neurobiol Dis 71:140\u2013150","journal-title":"Neurobiol Dis"},{"key":"25_CR35","doi-asserted-by":"publisher","first-page":"8257","DOI":"10.1073\/pnas.1400988111","volume":"111","author":"A Chiarlone","year":"2014","unstructured":"Chiarlone A, Bellocchio L, Bl\u00e1zquez C et al (2014) A restricted population of CB1 cannabinoid receptors with neuroprotective activity. Proc Natl Acad Sci U S A 111:8257\u20138262","journal-title":"Proc Natl Acad Sci U S A"},{"key":"25_CR36","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/brain\/awq278","volume":"134","author":"C Bl\u00e1zquez","year":"2011","unstructured":"Bl\u00e1zquez C, Chiarlone A, Sagredo O et al (2011) Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington\u2019s disease. Brain 134:119\u2013136","journal-title":"Brain"},{"key":"25_CR37","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1038\/cdd.2015.11","volume":"22","author":"C Bl\u00e1zquez","year":"2015","unstructured":"Bl\u00e1zquez C, Chiarlone A, Bellocchio L et al (2015) The CB1 cannabinoid receptor signals striatal neuroprotection via a PI3K\/Akt\/mTORC1\/BDNF pathway. Cell Death Differ 22:1618\u20131629","journal-title":"Cell Death Differ"},{"key":"25_CR38","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.ejmg.2013.05.007","volume":"56","author":"E Kloster","year":"2013","unstructured":"Kloster E, Saft C, Epplen JT, Arning L (2013) CNR1 variation is associated with the age at onset in Huntington disease. Eur J Med Genet 56:416\u2013419","journal-title":"Eur J Med Genet"},{"key":"25_CR39","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.nbd.2011.03.006","volume":"42","author":"S Mievis","year":"2011","unstructured":"Mievis S, Blum D, Ledent C (2011) Worsening of Huntington disease phenotype in CB1 receptor knockout mice. Neurobiol Dis 42:524\u2013529","journal-title":"Neurobiol Dis"},{"key":"25_CR40","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1038\/sj.bjp.0707495","volume":"152","author":"BT McIntosh","year":"2007","unstructured":"McIntosh BT, Hudson B, Yegorova S et al (2007) Agonist-dependent cannabinoid receptor signalling in human trabecular meshwork cells. Br J Pharmacol 152:1111\u20131120","journal-title":"Br J Pharmacol"},{"key":"25_CR41","doi-asserted-by":"publisher","first-page":"24845","DOI":"10.1074\/jbc.M114.557025","volume":"289","author":"RB Laprairie","year":"2014","unstructured":"Laprairie RB, Bagher AM, Kelly ME et al (2014) Type 1 cannabinoid receptor ligands display functional selectivity in a cell culture model of striatal medium spiny projection neurons. J Biol Chem 289:24845\u201324862","journal-title":"J Biol Chem"},{"key":"25_CR42","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1124\/mol.115.099192","volume":"88","author":"E Khajehali","year":"2015","unstructured":"Khajehali E, Malone DT, Glass M et al (2015) Biased agonism and biased allosteric modulation at the CB1 cannabinoid receptor. Mol Pharmacol 88:368\u2013379","journal-title":"Mol Pharmacol"},{"key":"25_CR43","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1124\/mol.115.101980","volume":"89","author":"RB Laprairie","year":"2016","unstructured":"Laprairie RB, Bagher AM, Kelly ME, Denovan-Wright EM (2016) Biased type 1 cannabinoid receptor signaling influences neuronal viability in a cell culture model of Huntington disease. Mol Pharmacol 89:364\u2013375","journal-title":"Mol Pharmacol"},{"key":"25_CR44","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.neuroscience.2010.06.056","volume":"170","author":"MJ Dowie","year":"2010","unstructured":"Dowie MJ, Howard ML, Nicholson LF et al (2010) Behavioural and molecular consequences of chronic cannabinoid treatment in Huntington\u2019s disease transgenic mice. Neuroscience 170:324\u2013336","journal-title":"Neuroscience"},{"issue":"35","key":"25_CR45","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.tips.2014.04.007","volume":"2014","author":"JD Violin","year":"2014","unstructured":"Violin JD, Crombie AL, Soergel DG, Lark MW (2014) Biased ligands at G-protein-coupled receptors: promise and progress. Trends Pharmacol Sci 2014(35):308\u2013316","journal-title":"Trends Pharmacol Sci"},{"key":"25_CR46","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/nrd3954","volume":"12","author":"T Kenakin","year":"2013","unstructured":"Kenakin T, Christopoulos A (2013) Signalling bias in new drug discovery: detection, quantification and therapeutic impact. Nat Rev Drug Discov 12:205\u2013216","journal-title":"Nat Rev Drug Discov"},{"key":"25_CR47","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1098\/rspb.1983.0093","volume":"220","author":"JW Black","year":"1983","unstructured":"Black JW, Leff P (1983) Operational models of pharmacological agonism. Proc R Soc Lond B Biol Sci 220:141\u2013162","journal-title":"Proc R Soc Lond B Biol Sci"},{"key":"25_CR48","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1124\/mol.114.096503","volume":"87","author":"EL Stahl","year":"2015","unstructured":"Stahl EL, Zhou L, Ehlert FJ, Bohn LM (2015) A novel method for analyzing extremely biased agonism at G protein-coupled receptors. Mol Pharmacol 87:866\u2013877","journal-title":"Mol Pharmacol"},{"key":"25_CR49","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.ab.2004.11.015","volume":"338","author":"H Chen","year":"2005","unstructured":"Chen H, Kovar J, Sissons S et al (2005) A cell based immunocytochemical assay for monitoring kinase signaling pathways and drug efficacy. Anal Biochem 338:136\u2013142","journal-title":"Anal Biochem"},{"key":"25_CR50","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.ab.2004.05.011","volume":"333","author":"S Wong","year":"2004","unstructured":"Wong S (2004) A 384-well cell-based phospho-ERK assay for dopamine D2 and D3 receptors. Anal Biochem 333:265\u2013272","journal-title":"Anal Biochem"},{"key":"25_CR51","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/978-1-4939-2718-0_13","volume":"1314","author":"V Boveia","year":"2015","unstructured":"Boveia V, Schutz-Geschwender A (2015) Quantitative analysis of signal transduction with in-cell western immunofluorescence assays. Methods Mol Biol 1314:115\u2013130","journal-title":"Methods Mol Biol"},{"key":"25_CR52","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.neuropharm.2007.06.005","volume":"54","author":"TL Daigle","year":"2008","unstructured":"Daigle TL, Kearn CS, Mackie K (2008) Rapid CB1 cannabinoid receptor desensitization defines the time course of ERK1\/2 MAP kinase signaling. Neuropharmacology 54:36\u201344","journal-title":"Neuropharmacology"},{"key":"25_CR53","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1111\/j.1476-5381.2010.00681.x","volume":"160","author":"BD Hudson","year":"2010","unstructured":"Hudson BD, H\u00e9bert TE, Kelly ME (2010) Physical and functional interaction between CB1 cannabinoid receptors and beta2-adrenoceptors. Br J Pharmacol 160:627\u2013642","journal-title":"Br J Pharmacol"},{"key":"25_CR54","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.neuropharm.2013.04.006","volume":"72","author":"RB Laprairie","year":"2013","unstructured":"Laprairie RB, Kelly ME, Denovan-Wright EM (2013) Cannabinoids increase type 1 cannabinoid receptor expression in a cell culture model of striatal neurons: implications for Huntington\u2019s disease. Neuropharmacology 72:47\u201357","journal-title":"Neuropharmacology"},{"key":"25_CR55","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.ejphar.2013.09.002","volume":"721","author":"AM Bagher","year":"2013","unstructured":"Bagher AM, Laprairie RB, Kelly ME, Denovan-Wright EM (2013) Co-expression of the human cannabinoid receptor coding region splice variants (hCB1) affects the function of hCB1 receptor complexes. Eur J Pharmacol 721:341\u2013354","journal-title":"Eur J Pharmacol"},{"key":"25_CR56","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1124\/mol.116.103465","volume":"89","author":"AM Bagher","year":"2016","unstructured":"Bagher AM, Laprairie RB, Kelly ME, Denovan-Wright EM (2016) Antagonism of dopamine receptor 2 long affects cannabinoid receptor 1 signaling in a cell culture model of striatal medium spiny projection neurons. Mol Pharmacol 89:652\u2013666","journal-title":"Mol Pharmacol"},{"key":"25_CR57","unstructured":"Miller JW (2004) Tracking G protein-coupled receptor trafficking using odyssey imaging. \nhttp:\/\/www.licor.com\/bio\/PDF\/Miller_GPCR.pdf\n\n. Accessed 1 Mar 2010"},{"key":"25_CR58","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1124\/jpet.107.120857","volume":"321","author":"MT Griffin","year":"2007","unstructured":"Griffin MT, Figueroa KW, Liller S, Ehlert FJ (2007) Estimation of agonist activity at G protein-coupled receptors: analysis of M2 muscarinic receptor signaling through Gi\/o, Gs, and G15. J Pharmacol Exp Ther 321:1193\u20131207","journal-title":"J Pharmacol Exp Ther"},{"key":"25_CR59","doi-asserted-by":"crossref","unstructured":"Ehlert FJ, Suga H, Griffin MT (2011) Quantifying agonist activity at G protein-coupled receptors. J Vis Exp (58):e3179","DOI":"10.3791\/3179"},{"key":"25_CR60","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.tips.2015.05.008","volume":"36","author":"FJ Ehlert","year":"2015","unstructured":"Ehlert FJ (2015) Functional studies cast light on receptor states. Trends Pharmacol Sci 36:596\u2013604","journal-title":"Trends Pharmacol Sci"},{"key":"25_CR61","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/978-1-4939-2914-6_11","volume":"1335","author":"T Kenakin","year":"2015","unstructured":"Kenakin T (2015) The measurement of receptor signaling bias. Methods Mol Biol 1335:163\u2013176","journal-title":"Methods Mol Biol"},{"key":"25_CR62","doi-asserted-by":"publisher","first-page":"19144","DOI":"10.1073\/pnas.0509588102","volume":"102","author":"JE Lauckner","year":"2005","unstructured":"Lauckner JE, Hille B, Mackie K (2005) The cannabinoid agonist WIN55,212-2 increases intracellular calcium via CB1 receptor coupling to Gq\/11 G proteins. Proc Natl Acad Sci U S A 102:19144\u201319149","journal-title":"Proc Natl Acad Sci U S A"},{"key":"25_CR63","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1042\/bj2620643","volume":"262","author":"G Milligan","year":"1989","unstructured":"Milligan G, Unson CG, Wakeman DJO (1989) Cholera toxin treatment produces down-regulation of the \u03b1-subunit of the stimulatory guanine-nucleotide-binding protein (Gs). Biochem J 262:643\u2013649","journal-title":"Biochem J"},{"key":"25_CR64","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/j.cellsig.2008.02.016","volume":"20","author":"Y Obara","year":"2008","unstructured":"Obara Y, Okano Y, Ono S et al (2008) \u03b2\u03b3 subunits of G(i\/o) suppress EGF-induced ERK5 phosphorylation, whereas ERK1\/2 phosphorylation is enhanced. Cell Signal 20:1275\u20131283","journal-title":"Cell Signal"},{"key":"25_CR65","doi-asserted-by":"publisher","first-page":"27050","DOI":"10.1074\/jbc.C112.387332","volume":"287","author":"ML Rives","year":"2012","unstructured":"Rives ML, Rossillo M, Liu-Chen LY, Javitch JA (2012) 6\u2032-Guanidinonaltrindole (6\u2032-GNTI) is a G protein-biased \u03ba-opioid receptor agonist that inhibits arrestin recruitment. J Biol Chem 287:27050\u201327054","journal-title":"J Biol Chem"},{"key":"25_CR66","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/nature10939","volume":"485","author":"H Wu","year":"2012","unstructured":"Wu H, Wacker D, Mileni M et al (2012) Structure of the human \u03ba-opioid receptor in complex with JDTic. Nature 485:327\u2013332","journal-title":"Nature"}],"container-title":["Methods in Molecular Biology","Huntington\u2019s Disease"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-4939-7825-0_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,7,26]],"date-time":"2018-07-26T09:10:58Z","timestamp":1532596258000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-1-4939-7825-0_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"ISBN":["9781493978243","9781493978250"],"references-count":66,"URL":"https:\/\/doi.org\/10.1007\/978-1-4939-7825-0_25","relation":{"is-part-of":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1007\/978-1-4939-7825-0","asserted-by":"object"}]},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018]]}}}